Stopping venetoclax and azacitidine in AML remission
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether it's safe to stop the combination of venetoclax and azacitidine (VEN-AZA) in people with AML whose cancer has completely disappeared and who have no detectable leukemia cells left. If you've been on VEN-AZA for about a year and are in deep remission, this study may help you avoid unnecessary treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have AML (acute myeloid leukemia) that hasn't been treated before, and you started with a combination of venetoclax and azacitidine (called VEN-AZA)
- You've been on VEN-AZA for about 12 months
- Your AML is in complete remission (no leukemia found in bone marrow, and blood counts are back to normal or near-normal)
- A special test (like flow cytometry or a gene test) shows no remaining leukemia cells — called minimal residual disease or MRD-negative
- You are well enough to be active (ECOG score under 3) and able to follow study appointments
- You haven't had a stem cell transplant before, and you aren't stopping VEN-AZA because it stopped working
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This trial tests whether the combination of venetoclax and azacitidine can clear small amounts of leukemia cells that remain after initial chemotherapy (called measurable residual disease or MRD). It is for people with acute myeloid leukemia who have MRD before a stem cell transplant.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.